NCT04351347

Brief Summary

Efficacy of Ivermectin in larger doses in COVID-19 treatment

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for phase_2

Timeline
55mo left

Started Jun 2020

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress57%
Jun 2020Dec 2030

First Submitted

Initial submission to the registry

April 15, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 17, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

June 16, 2020

Completed
10.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

March 10, 2021

Status Verified

March 1, 2021

Enrollment Period

10.5 years

First QC Date

April 15, 2020

Last Update Submit

March 8, 2021

Conditions

COVID

Outcome Measures

Primary Outcomes (1)

  • Number of patients with improvement or died

    The number of patients with improvement or death

    1 month

Study Arms (2)

Ivermectin

EXPERIMENTAL

Ivermectin alone in larger doses

Drug: Ivermectin

Standard treatment

NO INTERVENTION

Standard of care treatment

Interventions

IvermectinDRUG

ivermectin

Ivermectin

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with covid 19

You may not qualify if:

  • Allergy or side effects to treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tanta University

Tanta, 35111, Egypt

RECRUITING

MeSH Terms

Interventions

Ivermectin

Intervention Hierarchy (Ancestors)

MacrolidesPolyketidesLactonesOrganic Chemicals

Study Officials

  • sherief Abd-Elsalam, Ass. Prof.

    Tanta University - Faculty of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sherief Abd-Elsalam, ass. prof.

CONTACT

00201147773440sheriefabdelsalam@yahoo.com

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass. Prof. Tropical Medicine

Study Record Dates

First Submitted

April 15, 2020

First Posted

April 17, 2020

Study Start

June 16, 2020

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2030

Last Updated

March 10, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)